J. Cain

发表

Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

M. Tomasson, L. Hennighausen, D. Link, 2008, The Journal of clinical investigation.

Wnt pathway inhibition via the targeting of Frizzled receptors results in decreased growth and tumorigenicity of human tumors

M. Fischer, J. Lewicki, A. Gurney, 2012, Proceedings of the National Academy of Sciences.

Mcl 1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia

T. Ley, J. Payton, M. Tomasson, 2010 .

A delta T-cell receptor deleting element transgenic reporter construct is rearranged in alpha beta but not gamma delta T-cell lineages

R. Hockett, J. Shutter, J. Cain, 1995, Molecular and cellular biology.

Targeting the Wnt signaling pathway through R-spondin 3 identifies an anti-fibrosis treatment strategy for multiple organs

D. Brenner, J. Lachowicz, A. Gurney, 2020, PloS one.

Csf 3 r mutations in mice confer a strong clonal HSC advantage via activation of Stat 5

M. Tomasson, L. Hennighausen, D. Link, 2008 .

An activated receptor tyrosine kinase, TEL/PDGFβR, cooperates with AML1/ETO to induce acute myeloid leukemia in mice

M. Tomasson, J. Cain, J. O’Neal, 2003, Proceedings of the National Academy of Sciences of the United States of America.

Myeloproliferative disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.

M. Tomasson, L. Hennighausen, Zhifu Xiang, 2006, Blood.

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Intratumoral heterogeneity generated by Notch signaling promotes small cell lung cancer

K. Garcia, M. Fischer, J. Sage, 2017, Nature.

RSPO3 antagonism inhibits growth and tumorigenicity in colorectal tumors harboring common Wnt pathway mutations

M. Fischer, T. Hoey, F. Cattaruzza, 2017, Scientific Reports.

alpha beta but not gamma delta T-cell lineages. transgenic reporter construct is rearranged in A delta T-cell receptor deleting element

R. Hockett, J. Shutter, J. Cain, 2013 .

WNT antagonists exhibit unique combinatorial antitumor activity with taxanes by potentiating mitotic cell death

M. Fischer, J. Lewicki, A. Gurney, 2017, Science Advances.

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

T. Ley, J. Payton, M. Tomasson, 2009, The Journal of clinical investigation.

Neoplasia Driven by Mutant c-KIT Is Mediated by Intracellular, Not Plasma Membrane, Receptor Signaling

Michael H. Tomasson, Jennifer Cain, M. Tomasson, 2006, Molecular and Cellular Biology.

Therapeutic Targeting of Tumor-Derived R-Spondin Attenuates β-Catenin Signaling and Tumorigenesis in Multiple Cancer Types.

M. Fischer, J. Lewicki, A. Gurney, 2016, Cancer research.

Complete remission of TEL-PDGFRB-induced myeloproliferative disease in mice by receptor tyrosine kinase inhibitor SU11657.

M. Tomasson, J. Cain, A Douglas Laird, 2004, Blood.

Abstract 404: Development of a RSPO3 CLIA-validated assay as a predictive biomarker for response to anti-RSPO3 antibody treatment in patients with solid tumors

M. Fischer, J. Lewicki, A. Gurney, 2016 .

Abstract 3728: Anti-Notch1 antibody (OMP-52M51) impedes tumor growth and cancer stem cell frequency (CSC) in a chemo-refractory breast cancer xenograft model with an activating Notch1 mutation and screening for activated Notch1 across multiple solid tumor types.

L. Esserman, J. Lewicki, A. Gurney, 2013 .

Targeting Notch Signaling with a Notch2/Notch3 Antagonist (Tarextumab) Inhibits Tumor Growth and Decreases Tumor-Initiating Cell Frequency

M. Fischer, J. Lewicki, A. Gurney, 2015, Clinical Cancer Research.

Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.

M. Tomasson, L. Hennighausen, D. Link, 2008, The Journal of clinical investigation.

Therapeutic targeting of tumor-derived R-spondin attenuates β-catenin signaling and tumorigenesis in multiple cancer types

J. Lewicki, A. Gurney, T. Hoey, 2015 .

Mcl1 haploinsufficiency protects mice from Myc-induced acute myeloid leukemia.

T. Ley, J. Payton, M. Tomasson, 2010, The Journal of clinical investigation.